Free Cervical Cancer Screening for Underprivileged Women to be Provided by QIAGEN in Partnership with Cancer Foundation of China Free HPV Testing to be Offered on International Women's Day
Beijing (ANTARA News/PRNewswire-AsiaNet) - Free human papillomavirus (HPV) testing will
be offered to underprivileged women by QIAGEN at 31 hospitals throughout China on March 8, International Women's Day.
HPV is the primary cause of cervical cancer, and the program is part of a nationwide prevention campaign organized by the Cancer Foundation of China and partially sponsored by QIAGEN.
"Cervical cancer is the second-most-common cancer affecting women worldwide," said Prof. Qiao Youlin, general director of the event and Chief of the Department of Cancer Epidemiology at the Cancer Institute, Chinese Academy of Medical Sciences.
"By testing women over the age of 30 for the virus that causes the disease, we can significantly improve our ability to identify women at risk. When used along with the Pap, QIAGEN's digene(R) HPV Test can help drastically reduce the annual number of cervical cancer deaths in China and around the world."
In partnering with the Cancer Foundation of China, QIAGEN will provide HPV testing kits to the 31 hospitals taking part in the event. These kits will be used in the screening of more than 3,000 underprivileged women throughout China.
"We believe that with greater awareness and widespread testing, cervical cancer can, and should, become a tragedy of the past," said Dr. Victor Shi, President of QIAGEN Asia.
"That means that the best in preventive care -- including HPV testing -- must be available to all eligible women. We are proud to partner with the Cancer Foundation of China to help make this goal a reality on International Women's Day."
About HPV and Cervical Cancer: Cervical cancer affects nearly 500,000 women around the world every year and kills more than 250,000. In Asia, about 265,000 women are diagnosed with cervical cancer every year (46,000 in China), and there are 143,000 deaths (26,000 in China). The disease is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that up to 80 percent of women will get an HPV infection at some point in their lives.
However, in most cases, the infection goes away or is suppressed by the body without causing problems. Only an infection that persists can cause abnormal cells that may develop into cervical cancer if not detected and treated early.
Routine HPV testing is recommended for older women, who are most likely to have infections that won't go away and thus most at risk of developing cervical cancer. In the United States, the FDA has approved HPV testing along with the Pap for all women over the age of 30.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products, including the only FDA- approved and CE-marked test for HPV (marketed as the digene(R) HPV Test).
QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions.
The company's products are sold to academic research markets, leading pharmaceutical and biotechnology companies, applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) and molecular diagnostics laboratories. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries; the company employs more than 2,600 people worldwide.
Further information about QIAGEN can be found at www.qiagen.com. Further information about HPV DNA testing can be found at www.theHPVtest.com.
About the Cancer Foundation of China:
The Cancer Foundation of China was founded on Oct. 26, 1984. It is a national, non-profit foundation that aims to push forward the development of cancer research, prevention and treatment in China. The scope of the foundation covers various aspects of the cancer research, prevention and treatment, including communications, education and training, prevention and control, fundamental research, application, clinical research, and rehabilitation and analgesia.
SOURCE: QIAGEN
CONTACT: Asia/Pacific, Brendan Green, +86-21-38653824,
Brendan.Green@qiagen.com; or Global, Pam Rasmussen,
+1-240-686-7616, Pamela.Rasmussen@qiagen.com, both of QIAGEN
Web site: http://www.qiagen.com
http://www.theHPVtest.com
Beijing (ANTARA News/PRNewswire-AsiaNet) - Free human papillomavirus (HPV) testing will
be offered to underprivileged women by QIAGEN at 31 hospitals throughout China on March 8, International Women's Day.HPV is the primary cause of cervical cancer, and the program is part of a nationwide prevention campaign organized by the Cancer Foundation of China and partially sponsored by QIAGEN.
"Cervical cancer is the second-most-common cancer affecting women worldwide," said Prof. Qiao Youlin, general director of the event and Chief of the Department of Cancer Epidemiology at the Cancer Institute, Chinese Academy of Medical Sciences.
"By testing women over the age of 30 for the virus that causes the disease, we can significantly improve our ability to identify women at risk. When used along with the Pap, QIAGEN's digene(R) HPV Test can help drastically reduce the annual number of cervical cancer deaths in China and around the world."
In partnering with the Cancer Foundation of China, QIAGEN will provide HPV testing kits to the 31 hospitals taking part in the event. These kits will be used in the screening of more than 3,000 underprivileged women throughout China.
"We believe that with greater awareness and widespread testing, cervical cancer can, and should, become a tragedy of the past," said Dr. Victor Shi, President of QIAGEN Asia.
"That means that the best in preventive care -- including HPV testing -- must be available to all eligible women. We are proud to partner with the Cancer Foundation of China to help make this goal a reality on International Women's Day."
About HPV and Cervical Cancer: Cervical cancer affects nearly 500,000 women around the world every year and kills more than 250,000. In Asia, about 265,000 women are diagnosed with cervical cancer every year (46,000 in China), and there are 143,000 deaths (26,000 in China). The disease is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that up to 80 percent of women will get an HPV infection at some point in their lives.
However, in most cases, the infection goes away or is suppressed by the body without causing problems. Only an infection that persists can cause abnormal cells that may develop into cervical cancer if not detected and treated early.
Routine HPV testing is recommended for older women, who are most likely to have infections that won't go away and thus most at risk of developing cervical cancer. In the United States, the FDA has approved HPV testing along with the Pap for all women over the age of 30.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading provider of innovative sample and assay technologies and products, including the only FDA- approved and CE-marked test for HPV (marketed as the digene(R) HPV Test).
QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions.
The company's products are sold to academic research markets, leading pharmaceutical and biotechnology companies, applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) and molecular diagnostics laboratories. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries; the company employs more than 2,600 people worldwide.
Further information about QIAGEN can be found at www.qiagen.com. Further information about HPV DNA testing can be found at www.theHPVtest.com.
About the Cancer Foundation of China:
The Cancer Foundation of China was founded on Oct. 26, 1984. It is a national, non-profit foundation that aims to push forward the development of cancer research, prevention and treatment in China. The scope of the foundation covers various aspects of the cancer research, prevention and treatment, including communications, education and training, prevention and control, fundamental research, application, clinical research, and rehabilitation and analgesia.
SOURCE: QIAGEN
CONTACT: Asia/Pacific, Brendan Green, +86-21-38653824,
Brendan.Green@qiagen.com; or Global, Pam Rasmussen,
+1-240-686-7616, Pamela.Rasmussen@qiagen.com, both of QIAGEN
Web site: http://www.qiagen.com
http://www.theHPVtest.com
COPYRIGHT © 2008
No comments:
Post a Comment